GILD vs. GSK: Gilead Sciences vs. GSK Stock Comparison

Company Profile

Gilead Sciences (GILD) and GSK (GSK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GILD is classified in Biotechnology while GSK is classified in Pharmaceuticals.

Gilead Sciences (GILD) trades as ordinary local shares, while GSK (GSK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Gilead Sciences (GILD) reports a negative ROE of -22.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile GSK (GSK) reports 28.27%, ranking against industry peers normally.

Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile GSK (GSK) reports 12.97%, ranking against industry peers normally.

Both Gilead Sciences (GILD) at 42.43% and GSK (GSK) at 32.14% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Gilead Sciences (GILD) at 2.39% and GSK (GSK) at 4.11% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both companies show strong earnings momentum, but Gilead Sciences (GILD) at 1,684.21% is the standout with EPS growth above its industry range; GSK (GSK) at 123.15% also sits in the top quartile.

Growth Metrics

Financial Strength

Both Gilead Sciences (GILD) at 1.38 and GSK (GSK) at 0.86 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both balance sheets lean debt-heavy versus peers, but GILD is more stretched: GSK (GSK) at 1.30 sits in the higher-leverage quartile and Gilead Sciences (GILD) at 2.02 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Both Gilead Sciences (GILD) at 1.94% and GSK (GSK) at 1.57% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Gilead Sciences (GILD) at 43.46% and GSK (GSK) at 63.33% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: GSK (GSK) trades at 17.54 times trailing earnings, ranked against its peers, while Gilead Sciences (GILD) has no P/E ratio this period.

GSK (GSK) at 3.01 sits in the cheaper P/S ratio quartile while Gilead Sciences (GILD) at 6.68 prices around its industry’s middle — GSK costs less per dollar of sales, though read it alongside growth and margins.

GSK (GSK) at 4.02 sits near its industry’s typical P/B ratio, while Gilead Sciences (GILD) at 15.88 prices above its benchmark range — GILD looks rich relative to book.

Valuation Metrics